Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD +1.74%16 EV-to-OCF is 45.52 as of Aug. 10, 2026, which is 40% below its 10-year median of 75.82. GuruFocus rates XSWX:GALD with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Galderma Group AG ranks worse than 86.38% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Galderma Group AG's Enterprise Value is CHF43,814 Mil.
Galderma Group AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF962 Mil. Therefore, Galderma Group AG's EV-to-OCF for today is 45.52.
The historical rank and industry rank for Galderma Group AG's EV-to-OCF or its related term are showing as below:
XSWX:GALD'
s EV-to-OCF Range Over the Past 10 Years
Min: 37.33 Med: 75.82 Max: 194.68
Current: 45.52
During the past 5 years, the highest EV-to-OCF of Galderma Group AG was 194.68. The lowest was 37.33. And the median was 75.82.
XSWX:GALD's EV-to-OCF is ranked worse than 86.38% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.1
vs XSWX:GALD: 45.52
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galderma Group AG (XSWX:GALD) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galderma Group AG's PE Ratio (TTM) for today is calculated as:
Galderma Group AG's share price for today is CHF181.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF2.914.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Galderma Group AG EV-to-OCF Related Terms
Galderma Group AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's EV-to-OCF falls into.
Galderma Group AG's current Enterprise Value is CHF43,814 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF962 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a EV-to-OCF of 45.52 as of Aug. 10, 2026. This is 40% below median its historical median of 75.82. Over the past decade, Galderma Group AG's EV-to-OCF has ranged from 37.33 to 194.68. According to the industry distribution chart, Galderma Group AG ranks #869 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 86.4%.
Is Galderma Group AG's EV-to-OCF too high?
Galderma Group AG's current EV-to-OCF of 45.52 is 40% below median its 10-year median of 75.82. Over the past 10 years, this metric has ranged from a low of 37.33 to a high of 194.68. The Drug Manufacturers industry median EV-to-OCF is 11.10. Galderma Group AG's value of 45.52 is 310.1% above this industry median. Based on the distribution chart, Galderma Group AG ranks #869 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #869 out of 1006 companies for EV-to-OCF. This places Galderma Group AG in the lower half of its industry. The industry median EV-to-OCF is 11.10. Galderma Group AG's value of 45.52 is 310.1% above this benchmark. Historically, Galderma Group AG's own EV-to-OCF has ranged from 37.33 to 194.68 over the past decade. While the company's 10-year median is 75.82 vs. the industry median of 11.10, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.10, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current EV-to-OCF of 45.52 is 310.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current EV-to-OCF is 45.52, which is 40% below median its own 10-year median of 75.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current EV-to-OCF of 45.52. The current EV-to-OCF is 45.52, which is 40% below median its 10-year median of 75.82 and 310.1% above the Drug Manufacturers industry median of 11.10. Galderma Group AG's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current EV-to-OCF is 45.52 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
16GF Score
Get the complete analysis for XSWX:GALD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
